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Amyotrophic lateral sclerosis (ALS) is an adult-onset degenerative disorder characterized by the death of motor
neurons in the cortex, brain stem, and spinal cord. Despite intensive research the basic pathophysiology of ALS
remains unclear. Although most cases are sporadic, ∼10% of ALS cases are familial (FALS). Mutations in the Cu/
Zn superoxide dismutase (SOD1) gene cause ∼20% of FALS. The gene(s) responsible for the remaining 80% of
FALS remain to be found. Using a large European kindred without SOD1 mutation and with classic autosomal
dominant adult-onset ALS, we have identified a novel locus by performing a genome scan and linkage analysis.
The maximum LOD score is 4.5 at recombination fraction 0.0, for polymorphism D18S39. Haplotype analysis
has identified a 7.5-cM, 8-Mb region of chromosome 18q21, flanked by markers D18S846 and D18S1109, as a
novel FALS locus.
Amyotrophic lateral sclerosis (ALS) is an adult-onset de-
generative disorder characterized by the death of motor
neurons in the cortex, brain stem, and spinal cord. The
result is progressive muscle weakness, atrophy, and
death from respiratory paralysis usually within 3–5 years
of symptom onset (Brown 1995). The age-adjusted
worldwide incidence of ALS is 0.5–3 per 100,000, with-
out obvious race-related differences (Smith and Appel
1995), and the prevalence is 4–6 per 100,000 (Haver-
kamp et al. 1995). Approximately 10% of ALS cases
are familial (FALS) (Camu et al. 1999), with the majority
of cases deemed, in the absence of a positive family his-
tory, to be sporadic (SALS). With the exception of some
FALS cases with clearly distinct features, the majority of
FALS and SALS cases are clinically indistinguishable. A
distinct ALS phenotype is seen in the Pacific islands of
Guam, where the Chamorro people have had an unu-
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sually high incidence of parkinsonism-dementia ALS (de
Belleroche et al. 1995).
The diagnosis of ALS requires the presence of both
upper and lower motor-neuron features, with disease
progression, in the absence of evidence of another dis-
ease that may explain these signs. Dementia is found in
a portion of patients; estimates vary from 3%–5% (Al
Chalabi and Leigh 2000) to 15% (Hudson 1981). At
present, there is no cure for ALS, and treatment is pri-
marily palliative.
The underlying cause of ALS remains unknown, and,
although it comprises only 10% of cases, FALS is com-
monly studied, with the aim of mapping the gene(s) that
cause or predispose to ALS. Identification of FALS genes
may lead to a greater understanding of the mechanisms
of cell death in all forms of ALS. This, in turn, may lead
to more-effective therapies.
Several FALS loci have been identified. ALS1 (MIM
105400) is an adult-onset autosomal dominant form of
the disease. Linkage to chromosome 21q has been estab-
lished (Siddique et al. 1991), with evidence of genetic
heterogeneity (King et al. 1993). Subsequently, mutations
have been detected in the Cu/Zn superoxide dismutase
gene (SOD1) (Rosen et al. 1993). Adult-onset autosomal
dominant FALS neither linked to chromosome 21 nor
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associated with mutations in the SOD1 gene is designated
“ALS3” (Siddique et al. 1991). ALS4 (MIM 602433) is
the only identified autosomal dominant juvenile-onset
form of ALS and maps to chromosome 9q34 (Chance et
al. 1998). A detailed clinical account of several of the
family members, including autopsy reports, has deter-
mined that these individuals fulfill the ALS criteria but
display some additional pathological findings (Rabin et
al. 1999).
Autosomal recessive, juvenile-onset ALS (AR-ALS) ex-
ists in three forms. A family with type 3 was used to
map ALS2 (MIM 205100) to chromosome 2q33 (Hen-
tati et al. 1994). In this form of ALS, symptoms occur
during the 1st or 2d decade of life and progress slowly
for 10–15 years (Hentati et al. 1994). The causative gene
has recently been identified (Hadano et al. 2001). Type
1 is the most prevalent form of AR-ALS and has been
linked to chromosome 15q15.1-q21.1 (ALS5 [MIM
602099]) (Hentati et al. 1998). As yet, no locus for type
2 AR-ALS has been identified.
An ALS subtype that includes frontotemporal demen-
tia (ALS FTD [MIM 105550]) has been mapped to chro-
mosome 9q21-q22 (Hosler et al. 2000). Another ALS-
FTD locus, which also includes parkinsonian features,
is caused by mutations in the tau gene on chromosome
17q21 (Lynch et al. 1994). A 1998 report of an X-linked
dominant ALS locus (Siddique et al. 1998) has not been
further described.
Approximately 80% of FALS cases cannot be ex-
plained by SOD1 mutations; thus, other candidate genes
have been tested for a role in disease pathogenesis. The
role of neurofilaments in ALS has been intensely ex-
amined (Julien et al. 1999). The other isoforms of
SOD—that is, MnSOD (SOD2) and extracellular SOD
(SOD3)—have been examined, and, although neither is
linked to FALS (de Belleroche et al. 1995; Siddique and
Deng 1996), mutant SOD1-mediated disease in mice is
influenced by the expression of these SOD proteins (Li
et al. 1995; Melov et al. 1998, 1999; Andreassen et al.
2000). The neuronal apoptosis–inhibitor gene and the
survival motor neuron (SMN) gene, which are impli-
cated in spinal muscular atrophy, also have been studied
(de Belleroche et al. 1995; Orrell et al. 1997; Parboo-
singh et al. 1999), and, recently, the SMN locus has been
implicated in the modification of mutant SOD1 disease
in a transgenic mouse, a modification that delays dis-
ease onset significantly (Kunst et al. 2000). Other genes
that have been examined include the apolipoprotein E
gene (Bedlack et al. 2000), the apurinic/apyrimidinic ex-
onuclease gene (Hayward et al. 1999), and the persyn
gene (Flowers et al. 1999).
The highly cooperative ALS pedigree Fr017 has been
collected and assessed by neurologists expert in ALS
(J.K., F.S., V.M., and W.C.). In all, there are 51 collected
DNA samples. Figure 1 shows the most informative sec-
tion of the family. This ALS pedigree has 20 affected
individuals (definitely affected, by El Escorial ALS di-
agnostic criteria), and, although, as would be expected,
many are deceased, we have DNA from eight affected
members, and the structure of the pedigree is such that
the genotypes of five deceased affected individuals may
be confidently inferred. Clinically, the affected family
members have a rather uniform presentation of ALS,
beginning, for the majority of the patients, in the legs,
with a mean age at onset and a mean duration of 45
years and 5 years, respectively. Clinical presentation is
typical of ALS, with progressive weakness involving all
four limbs and bulbar level, with upper and lower motor-
neuron signs and diffuse denervation on electromyog-
raphy. There are no atypical features such as pain, de-
mentia, sensory signs, or cerebellar degeneration.
Blood was collected from all consenting family mem-
bers. DNA and lymphoblastoid cell lines (Anderson and
Gusella 1984) were generated. The study was approved
by the Montreal General Hospital Research Ethics Com-
mittee and the Assistance Publique des Hoˆpitaux de Paris
Ethics Committee.
SSCP analysis of the SOD1 gene was performed as
described elsewhere (Boukaftane et al. 1998), and, since
no mutation was detected in the family, a genome scan
was performed on the most informative portion of the
pedigree (22 individuals, including 7 affected with ALS),
by use of a panel of 400 highly polymorphic evenly
spaced microsatellite markers. All subsequent markers
used were polymorphic microsatellites ordered by the
Marshfield genetic maps (Center for Medical Genetics,
Marshfield Medical Research Foundation database).
Primer sequences were obtained from The Cooperative
Human Linkage Center database and from The Genome
Database. Genotyping was performed by PCR incor-
porating [35S]-dATP. Products were electrophoresed on
6% denaturing polyacrylamide gels, and then autora-
diography was performed. Alleles were sized by com-
parison to the M13mp18 sequence ladder. Marker-allele
sizes and frequencies were obtained from the Fondation
Jean Dausset CEPH database.
The genotype data was analyzed by the MLINK pro-
gram of the FASTLINK software package (Cottingham
et al. 1993). The model used for analysis was autosomal
dominant with incomplete and age-dependent pene-
trance of disease, with three liability classes based on
published values: (1) age 0–46 years, 50%; (2) age 47
years, 90%; and (3) spouses, 100%. The ages reflect the
age at onset, for affected family members, and the age
at last clinical exam, for those unaffected. Simulation
analysis using the same model was performed by SLINK
software (Ott 1989; Weeks 1990).
Analysis of the data generated by genome scan iden-
tified two regions suggestive of linkage—that is, for
which the LOD score was 11.5. Further analysis, using
Figure 1 Informative section of pedigree Fr017. Individuals available for typing are indicated by the generated genotype data. The markers examined are shown. Alleles in parentheses are
inferred. All inferred haplotypes were reconstructed on the basis of minimal recombinations. A solid black bar indicates the disease haplotype. A thin black line denotes an unknown or unphased
haplotype. Key recombinants (IV:37 and IV:67) are indicated by an asterisk (*). Alleles given refer to the Fondation Jean Dausset CEPH alleles, when available. Information is shown only for relevant
individuals. To preserve confidentiality, the sex of all individuals has been disguised; in addition, six unaffected haplotype carriers have been omitted from the pedigree.
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Table 1
LOD-Score Analysis, for the Most-Informative Markers, for ALS Pedigree Fr017
MARKERa (POSITION [cM])
LOD SCORE AT v p
.000 .010 .050 .100 .200 .300 .400
D18S846 (77.36) 6.460 1.447 .685 .354 .078 .015 .027
D18S39 (77.36) 4.523 4.448 4.141 3.737 2.861 1.892 .861
D18S35 (77.36) .223 .205 .148 .102 .059 .046 .033
D18S858 (80.41) 3.267 3.206 2.956 2.631 1.933 1.182 .435
D18S1103 (83.46) 1.822 1.816 1.756 1.627 1.261 .819 .355
D18S64 (84.80) 1.705 1.702 1.653 1.537 1.184 .738 .280
D18S1109 (84.80) a 1.395 .137 .283 .498 .429 .233
a Markers within the disease haplotype are underlined.
all available DNA samples and additional markers flank-
ing the positive regions, excluded linkage to a locus on
chromosome 12 and confirmed linkage to a novel locus
on chromosome 18.
Once suggestive linkage had been detected, testing for
linkage of nearby markers, with the entire set of family
samples, was performed. All available markers at this
locus ( ) were then investigated. Simulation-anal-np 30
ysis results indicate that the maximum LOD score
achievable with this pedigree under this model is 5.1 at
recombination fraction (v) .01. The maximum LOD
score obtained in this family is 4.5 at vp .0, for marker
D18S39, a result that is highly significant. Table 1 shows
the LOD scores obtained with the most informative
markers.
Once linkage was confirmed, a disease haplotype was
established on the basis of fine-mapping data and was
inferred when possible, while a minimum number of
recombination events was maintained (fig. 1). Key re-
combinants in two affected individuals (IV:37 and IV:
67) define the smallest common inherited segment. The
proximal recombination occurs between markers
D18S846 and D18S39 in IV:37. The distal recombina-
tion in individual IV:67 is between markers D18S64 and
D18S1109. All affected individuals carry the disease-
associated haplotype, and, although there are no affected
members without the haplotype, it is present in some
unaffected members, which probably reflects either re-
duced or age-dependent penetrance. Extensive genotyp-
ing in the region did not reveal increased homozygosity
or any other evidence for a large deletion.
Thus, at present, the flanking markers are D18S846
and D18S1109 and span an 7.5-cM, 8-Mb candidate re-
gion, which, according to current data, contains ∼50
genes, of which 13 are known and the remainder are
predicted (UCSC Human Genome Project Working Draft
database). Genes to be screened will be selected and pri-
oritized on the basis of their (a) expression patterns and
(b) function and possible involvement in ALS pathogen-
esis. At present, on the basis of its functional similarity
to SOD, the most obvious candidate gene is the thiore-
doxin-like (TXNL) gene (GenBank accession number
NM_004786; MIM 603049). The product of this gene
is a small disulfide-containing redox protein and is ex-
pressed in all tissues examined, including brain and CNS.
Screening of this gene by denaturing high-performance
liquid-chromatography analysis is in progress.
We have identified a novel FALS locus on chromosome
18 in a large autosomal dominant adult-onset ALS ped-
igree, thus representing the most common form of FALS.
The disease-gene interval has been mapped to a 7.5-cM
region flanked by markers D18S846 and D18S1109.
The aim of our future research will be to identify the
causative FALS gene in this pedigree, which will have
direct consequences in the field of motor-neuron–disease
research and treatment.
Another gene involved in ALS pathology may provide
crucial information about the biochemical pathways in-
volved, aid in diagnosis, and help to identify those at high
risk for the disease. The identification of a novel FALS
gene will have profound implications for patients with
ALS and for research and will aid in the development of
cellular and transgenic models of disease, models that may
accurately mimic the neuronal death seen in all forms of
ALS. This, in turn, may lead to more-effective therapy.
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